Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON: Baricitinib Combined With EVT for Acute Large Vessel Occlusion
NCT07449910Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in ischemic stroke, sponsored by The First Affiliated Hospital of University of Science and Technology of China. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07449910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449910.